Back to mobile site

Goldman Sachs on Bristol-Myers Squibb Co. (BMY): 'Complicated Setup for Upcoming Admilparant Phase 3 IPF Readout'

September 23, 2026 6:54 AM EDT Send to a Friend
Goldman Sachs analyst Asad Haider reiterated a Neutral rating and $63.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login